299075EGP
- Active ingredient
- selumetinib
- Strength
- 25mg
- Form
- capsule
- Manufacturer
- astrazeneca
- Route
- oral.solid
Uses
Used for the treatment of symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1.
Do not use if
No specific contraindications are listed in the prescribing information.
Side effects
Common adverse effects include gastrointestinal symptoms, skin reactions, elevated creatine phosphokinase, and fatigue.
Warnings
Monitor cardiac function, ocular health, gastrointestinal toxicity, and muscle-related adverse effects.
How it works
A MEK1/2 inhibitor that blocks signaling within the RAF-MEK-ERK pathway involved in abnormal cell growth.
Storage
Store at controlled room temperature according to manufacturer recommendations.